CoChat

Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism

Open access

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Abstract

The identification of brain-targeted autoantibodies in children with autism spectrum disorder (ASD) raises the possibility of autoimmune encephalopathy (AIE). Intravenous immunoglobulin (IVIG) is effective for AIE and for some children with ASD. Here, we present the largest case series of children with ASD treated with IVIG. Through an ASD clinic, we screened 82 children for AIE, 80 of them with ASD. IVIG was recommended for 49 (60%) with 31 (38%) receiving the treatment under our care team. The majority of parents (90%) reported some improvement with 71% reporting improvements in two or more symptoms. In a subset of patients, Aberrant Behavior Checklist (ABC) and/or Social Responsiveness Scale (SRS) were completed before and during IVIG treatment. Statistically significant improvement occurred in the SRS and ABC. The antidopamine D2L receptor antibody, the anti-tubulin antibody and the ratio of the antidopamine D2L to D1 receptor antibodies were related to changes in the ABC. The Cunningham Panel predicted SRS, ABC, parent-based treatment responses with good accuracy. Adverse effects were common (62%) but mostly limited to the infusion period. Only two (6%) patients discontinued IVIG because of adverse effects. Overall, our open-label case series provides support for the possibility that some children with ASD may benefit from IVIG. Given that adverse effects are not uncommon, IVIG treatment needs to be considered cautiously. We identified immune biomarkers in select IVIG responders but larger cohorts are needed to study immune biomarkers in more detail. Our small open-label exploratory trial provides evidence supporting a neuroimmune subgroup in patients with ASD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41398-018-0214-7

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flowchart for patient evaluation, criteria for diagnosis with autoimmune encephalopathy and recommended treatment
Fig. 1 Flowchart for patient evaluation, criteria for diagnosis with autoimmune encephalopathy and recommended treatmentCC BY · PubMed Central
Fig. 2 Changes in the Social Responsiveness Scale (SRS) and Aberrant Behavior Checklist (ABC) with intravenous immunoglobulin (IVIG) treatment
Fig. 2 Changes in the Social Responsiveness Scale (SRS) and Aberrant Behavior Checklist (ABC) with intravenous immunoglobulin (IVIG) treatmentCC BY · PubMed Central
Fig. 3 Baseline antibody titers are related to improvement in Aberrant Behavior Checklist (ABC) scores following intravenous immunoglobulin (IVIG). Greater improvement in ABC was related to high titers of antidopamine D2 receptor (D2L) antidopamine and anti-tubulin autoantibodies. A higher ratio of D2L to D1 antidopamine antibody titer was related to greater improvements in the irritability subscale of the ABC with IVIG treatment
Fig. 3 Baseline antibody titers are related to improvement in Aberrant Behavior Checklist (ABC) scores following intravenous immunoglobulin (IVIG). Greater improvement in ABC was related to high titers of antidopamine D2 receptor (D2L) antidopamine and anti-tubulin autoantibodies. A higher ratio of D2L to D1 antidopamine antibody titer was related to greater improvements in the irritability subscale of the ABC with IVIG treatmentCC BY · PubMed Central
Fig. 4 Responders to intravenous immunoglobulin (IVIG) was defined by the Social Responsiveness Scale (SRS) and Aberrant Behavior Checklist (ABC). Red squares are non-responders based on either questionnaire. Yellow diamonds were responders only based on the SRS but not the ABC. Blue triangles were responders based on the ABC but not the SRS. Green circles are responders based on both the ABC and SRS
Fig. 4 Responders to intravenous immunoglobulin (IVIG) was defined by the Social Responsiveness Scale (SRS) and Aberrant Behavior Checklist (ABC). Red squares are non-responders based on either questionnaire. Yellow diamonds were responders only based on the SRS but not the ABC. Blue triangles were responders based on the ABC but not the SRS. Green circles are responders based on both the ABC and SRSCC BY · PubMed Central
Fig. 5 Change in the total Aberrant Behavior Checklist (ABC) score over the first two years of treatment as compared to the average total ABC score prior to treatment. The figure is divided up into (a) treatment responders and (b) treatment non-responders, as defined by the ABC
Fig. 5 Change in the total Aberrant Behavior Checklist (ABC) score over the first two years of treatment as compared to the average total ABC score prior to treatment. The figure is divided up into (a) treatment responders and (b) treatment non-responders, as defined by the ABCCC BY · PubMed Central
Fig. 6 Case examples of responders to intravenous immunoglobulin (IVIG) treatment. Case #1 is a child with autism spectrum disorder (ASD) and mitochondrial dysfunction that had a sudden worsening in behavior at 8 years of age. a Initiating IVIG significantly improved behavior as measured by the Aberrant Behavior Checklist (ABC) and social function as measured by the Social Responsiveness Scale (SRS). b The writing sample on the left shows the patient’s handwriting a few months before IVIG treatment, and the sample on the right shows the patient’s handwriting 2 days after his first IVIG treatment. Case #2 is a boy with sudden regression found to have an N-Type Voltage-Gated Calcium-Channel autoantibody. c IVIG treatment significantly improved autoantibody titers. Case #3 is a girl with multiple regressions and severe ASD and related symptoms. d IVIG normalized CamKinase II activity but CamKinase II activity increased to abnormal levels and behavior, as measured by the ABC and SRS, worsened with increasing the IVIG treatment interval to every 6 weeks. Behavior improved after reinstating the original every 4 weeks dosing interval
Fig. 6 Case examples of responders to intravenous immunoglobulin (IVIG) treatment. Case #1 is a child with autism spectrum disorder (ASD) and mitochondrial dysfunction that had a sudden worsening in behavior at 8 years of age. a Initiating IVIG significantly improved behavior as measured by the Aberrant Behavior Checklist (ABC) and social function as measured by the Social Responsiveness Scale (SRS). b The writing sample on the left shows the patient’s handwriting a few months before IVIG treatment, and the sample on the right shows the patient’s handwriting 2 days after his first IVIG treatment. Case #2 is a boy with sudden regression found to have an N-Type Voltage-Gated Calcium-Channel autoantibody. c IVIG treatment significantly improved autoantibody titers. Case #3 is a girl with multiple regressions and severe ASD and related symptoms. d IVIG normalized CamKinase II activity but CamKinase II activity increased to abnormal levels and behavior, as measured by the ABC and SRS, worsened with increasing the IVIG treatment interval to every 6 weeks. Behavior improved after reinstating the original every 4 weeks dosing intervalCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Cited by

See all 67

Metadata

Authors
Connery, K., Tippett, M., Delhey, L. M., Rose, S., Slattery, J. C., Kahler, S. G., Hahn, J., Kruger, U., Cunningham, M. W., Shimasaki, C., & Frye, R. E.
Affiliations
  • University of Arkansas for Medical Sciences (US)
  • Rensselaer Polytechnic Institute (US)
  • University of Oklahoma Health Sciences Center (US)
  • Oklahoma Department of Transportation (US)
  • Barrow Neurological Institute (US)
Corresponding author
Frye, Richard E.
Venue
Translational Psychiatry
Published
2018-08-10
Volume
8
Issue
1
Pages
148-148
ISSN
2158-3188 (ISSN-L)
OpenAlex
W2885292966
Cited by
64
References
70
Citations by year
2026: 6 · 2025: 3 · 2024: 9 · 2023: 9 · 2022: 10 · 2021: 8 · 2020: 7 · 2019: 11 · 2018: 1
FWCI
4.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Translational Psychiatry (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Autism Research Institute
  • Arkansas Biosciences Institute
  • Children’s Hospital of Wisconsin Research Institute
Topics
  • Health Sciences › Medicine › Clinical Neurology › Autoimmune Neurological Disorders and Treatments
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
Keywords
intravenous immunoglobulin, autoimmune encephalopathy, autism spectrum disorder, anti-tubulin antibodies, Aberrant Behavior Checklist, Social Responsiveness Scale, treatment response, immunological markers, adverse effects
MeSH terms
Autism Spectrum Disorder, Adolescent, Ambulatory Care Facilities, Arkansas, Child, Child, Preschool, Encephalitis, Female, Humans, Male, Case-Control Studies, Immunoglobulins, Intravenous, Receptors, Dopamine D1, Hashimoto Disease, Administration, Intravenous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism. https://app.cochat.ai/papers/10.1038/s41398-018-0214-7
The paper
Connery, K., Tippett, M., Delhey, L. M., Rose, S., Slattery, J. C., Kahler, S. G., Hahn, J., Kruger, U., Cunningham, M. W., Shimasaki, C., & Frye, R. E. (2018). Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism. Translational Psychiatry. https://doi.org/10.1038/s41398-018-0214-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.